FDA accepts Orexo Zubsolv new drug application
Orexo, which expects the Zubsolv approval in July 2013, schedules the launch for September 2013. Orexo president and CEO Anders Lundstrom said, "We have a good chance of
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.